{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:07:58Z","timestamp":1793725678829,"version":"4.6.1"},"reference-count":24,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:sec id=\"ab-ooi230007-4\"><jats:title>Importance<\/jats:title><jats:p>The gold-standard treatment for laryngeal dystonia (LD) and essential tremor of the vocal tract (ETVT) is botulinum toxin (BoNT) chemodenervation. Although safe and effective, it is not curative, and periodic injections are required. Some medical insurance companies only cover injections at a 3-month interval, though some patients benefit from injections more frequently.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi230007-5\"><jats:title>Objective<\/jats:title><jats:p>To determine the proportion and characteristics of patients who receive BoNT chemodenervation treatment in intervals shorter than 90 days.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi230007-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This retrospective cohort study across 3 quaternary care neurolaryngology specialty practices in Washington and California recruited patients who underwent at least 4 consecutive laryngeal BoNT injections for LD and\/or ETVT in the past 5 years. Data were collected from March through June 2022 and analyzed from June through December 2022.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi230007-7\"><jats:title>Exposure<\/jats:title><jats:p>Laryngeal BoNT treatment.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi230007-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Biodemographic and clinical variables, injection characteristics, evolution during the 3 interinjection intervals, and lifetime laryngeal BoNT treatment data were collected from patient medical records. Logistic regression was used to assess association to the short-interval outcome, defined as an average injection interval shorter than 90 days.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi230007-9\"><jats:title>Results<\/jats:title><jats:p>Of 255 patients included from the 3 institutions, 189 (74.1%) were female, and the mean (SD) age was 62.7 (14.3) years. The predominant diagnosis was adductor LD (n\u2009=\u2009199 [78.0%]), followed by adductor dystonic voice tremor (n\u2009=\u200926 [10.2%]) and ETVT (n\u2009=\u200913 [5.1%]). Seventy patients (27.5%) received short-interval injections (&amp;amp;lt;90 days). The short-interval group was younger than the long-interval group (\u226590 days), with a mean (SD) age of 58.6 (15.5) years and 64.2 (13.5) years, respectively, and a mean difference of \u22125.7 years (95% CI, \u22129.6 to \u22121.8 years). There were no patient-related differences between the short- and long-interval groups in terms of sex, employment status, or diagnosis.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi230007-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This cohort study demonstrated that while insurance companies often mandate a 3-month or greater interval for BoNT chemodenervation financial coverage, there is a considerable subset of patients with LD and ETVT who receive short-interval treatment to optimize their vocal function. Short-interval chemodenervation injections demonstrate a similar adverse effect profile and do not appear to predispose to resistance through antibody formation.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoto.2023.0162","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T15:32:23Z","timestamp":1685028743000},"page":"615","source":"Crossref","is-referenced-by-count":5,"title":["Assessment of Patients Receiving Short-Interval Botulinum Toxin Chemodenervation Treatment for Laryngeal Dystonia and Essential Tremor of the Vocal Tract"],"prefix":"10.1001","volume":"149","author":[{"given":"Antonia","family":"Lagos-Villaseca","sequence":"first","affiliation":[{"name":"UCSF Voice and Swallowing Center, Department of Otolaryngology\u2013Head and Neck Surgery, University of California, San Francisco"},{"name":"Department of Otolaryngology, Pontificia Universidad Cat\u00f3lica de Chile, Santiago, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel K.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parirash","family":"Abdolhosseini","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonel","family":"Quinonez","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus F.","family":"Paoletti","sequence":"additional","affiliation":[{"name":"USC Voice Center, Department of Otolaryngology\u2013Head and Neck Surgery, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grant","family":"Gochman","sequence":"additional","affiliation":[{"name":"UCSF Voice and Swallowing Center, Department of Otolaryngology\u2013Head and Neck Surgery, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Johns","sequence":"additional","affiliation":[{"name":"USC Voice Center, Department of Otolaryngology\u2013Head and Neck Surgery, University of Southern California, Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clark A.","family":"Rosen","sequence":"additional","affiliation":[{"name":"UCSF Voice and Swallowing Center, Department of Otolaryngology\u2013Head and Neck Surgery, University of California, San Francisco"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Cheg","family":"Kao","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya K.","family":"Meyer","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology\u2013Head and Neck Surgery, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"ooi230007r1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1002\/lary.v123.S6","article-title":"Voice disorders in the workplace: productivity in spasmodic dysphonia and the impact of botulinum toxin.","volume":"123","author":"Meyer","year":"2013","journal-title":"Laryngoscope"},{"issue":"21","key":"ooi230007r2","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1212\/WNL.0000000000011922","article-title":"Laryngeal dystonia: multidisciplinary update on terminology, pathophysiology, and research priorities.","volume":"96","author":"Simonyan","year":"2021","journal-title":"Neurology"},{"issue":"2","key":"ooi230007r3","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1288\/00005537-198802000-00015","article-title":"Localized injections of botulinum toxin for the treatment of focal laryngeal dystonia (spastic dysphonia).","volume":"98","author":"Blitzer","year":"1988","journal-title":"Laryngoscope"},{"issue":"4","key":"ooi230007r4","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1001\/jamaoto.2017.3088","article-title":"Outcomes of onabotulinum toxin A treatment for adductor spasmodic dysphonia and laryngeal tremor.","volume":"144","author":"Patel","year":"2018","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"9","key":"ooi230007r5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1001\/jamaoto.2021.1745","article-title":"Association of laryngeal botulinum neurotoxin injection with work productivity for patients with spasmodic dysphonia.","volume":"147","author":"Meyer","year":"2021","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"4","key":"ooi230007r6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1001\/archotol.130.4.415","article-title":"Longitudinal effects of Botox injections on voice-related quality of life (V-RQOL) for patients with adductory spasmodic dysphonia: part II.","volume":"130","author":"Rubin","year":"2004","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"pt A","key":"ooi230007r7","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.toxicon.2015.07.013","article-title":"Explanation of timing of botulinum neurotoxin effects, onset and duration, and clinical ways of influencing them.","volume":"107","author":"Hallett","year":"2015","journal-title":"Toxicon"},{"issue":"3","key":"ooi230007r8","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/lary.21395","article-title":"Botulinum toxin treatment of adductor spasmodic dysphonia: longitudinal functional outcomes.","volume":"121","author":"Novakovic","year":"2011","journal-title":"Laryngoscope"},{"issue":"11","key":"ooi230007r9","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1111\/jocd.v19.11","article-title":"The mechanisms of action and use of botulinum neurotoxin type A in aesthetics: Key Clinical Postulates II.","volume":"19","author":"Nestor","year":"2020","journal-title":"J Cosmet Dermatol"},{"issue":"7","key":"ooi230007r10","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1007\/s00415-022-10995-2","article-title":"Time to onset and duration of botulinum toxin efficacy in movement disorders.","volume":"269","author":"Ledda","year":"2022","journal-title":"J Neurol"},{"issue":"1","key":"ooi230007r11","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jvoice.2020.04.021","article-title":"Practice patterns and barriers in botulinum toxin injection for the treatment of voice disorders.","volume":"36","author":"McGarey","year":"2022","journal-title":"J Voice"},{"issue":"6","key":"ooi230007r12","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.otohns.2005.09.008","article-title":"Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia.","volume":"133","author":"Blitzer","year":"2005","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"6","key":"ooi230007r13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1212\/WNL.0000000000003596","article-title":"Dystonia treatment: patterns of medication use in an international cohort.","volume":"88","author":"Pirio Richardson","year":"2017","journal-title":"Neurology"},{"issue":"1","key":"ooi230007r15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/toxins13010042","article-title":"Botulinum toxin in movement disorders: an update.","volume":"13","author":"Anandan","year":"2021","journal-title":"Toxins (Basel)"},{"issue":"2","key":"ooi230007r16","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.jvoice.2019.07.025","article-title":"Quality of life after botulinum toxin injection in patients with adductor spasmodic dysphonia; a systematic review and meta-analysis.","volume":"35","author":"Faham","year":"2021","journal-title":"J Voice"},{"issue":"2","key":"ooi230007r17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1177\/0194599816675320","article-title":"Effect of botulinum toxin and surgery among spasmodic dysphonia patients: a systematic review.","volume":"156","author":"van Esch","year":"2017","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"3","key":"ooi230007r18","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004327.pub2","article-title":"Botulinum toxin injections for the treatment of spasmodic dysphonia.","volume":"2004","author":"Watts","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"key":"ooi230007r19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/ene.2010.17.issue-s1","article-title":"Spasmodic dysphonia and botulinum toxin: experience from the largest treatment series.","volume":"17","author":"Blitzer","year":"2010","journal-title":"Eur J Neurol"},{"key":"ooi230007r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2019.112635","article-title":"Development of inhibition ELISA to detect antibody-induced failure of botulinum toxin a therapy in cosmetic indications.","volume":"473","author":"Srinoulprasert","year":"2019","journal-title":"J Immunol Methods"},{"issue":"1","key":"ooi230007r21","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1212\/WNL.0000000000006688","article-title":"High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy.","volume":"92","author":"Albrecht","year":"2019","journal-title":"Neurology"},{"issue":"1","key":"ooi230007r22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.3390\/medicina58010088","article-title":"The use of high initial doses of botulinum toxin therapy for cervical dystonia is a risk factor for neutralizing antibody formation: a monocentric cross-sectional pilot study.","volume":"58","author":"Hefter","year":"2022","journal-title":"Medicina (Kaunas)"},{"key":"ooi230007r23","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.2147\/CCID.S363321","article-title":"Causes of botulinum toxin treatment failure.","volume":"15","author":"Shtefan","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"4","key":"ooi230007r24","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1001\/archotol.126.4.533","article-title":"Resistance to botulinum toxin injections for spasmodic dysphonia.","volume":"126","author":"Smith","year":"2000","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"ooi230007r14","unstructured":"Position statement: botulinum toxin treatment. American Academy of Otolaryngology\u2013Head and Neck Surgery. April 21, 2021. Accessed April 11, 2023. https:\/\/www.entnet.org\/resource\/position-statement-botulinum-toxin-treatment\/"}],"container-title":["JAMA Otolaryngology\u2013Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2805500\/jamaotolaryngology_lagosvillaseca_2023_oi_230007_1688997597.84855.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T15:08:22Z","timestamp":1689260902000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2805500"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":24,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2023.0162","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}